XFOR
X4CNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
Current thesis
The bull case remains a funded execution story: a positive U.S. WHIM franchise, a pending European decision, and stated runway into 2028 give the company time to work through clinical and commercialization milestones.
Posture
Mixed
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta +1.7.
What can break
4WARD enrollment slippage would push out the later readout and keep the stock event-driven.
Momentum
56
Value
41
Sentiment
67
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $4.50 · Bull $8.50 · Bear $2.00
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-01 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-20 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-06-02
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade C · Mixed
Confidence Medium · Net Neutral
Target $9.33
Why
Momentum56 · Δ7d +13.7
Value41 · Δ7d +0.1
Sentiment67 · Δ7d +1.7
So what
Balanced signals (Net Neutral). Wait for confirmation before sizing up.
Lead driver: Sentiment · See AI snapshot
Momentum
56
34% active weight
Current posture
7d trendImproving
Δ7d
+13.7
Δ21d
-7.6
Value
41
32% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
+0.2
Sentiment
67
33% active weight
Current posture
7d trendImproving
Δ7d
+1.7
Δ21d
+2.7
Why this grade
Composite grade C. Momentum 55.6 / Value 41.1 / Sentiment 66.7
Fundamentals (TTM)As of 2026-06-01
Fundamentals (TTM)
As of 2026-06-01
Market Cap
$387.65M
Beta
0.46
Shares Out
87.44M
P/E (TTM) · Derived
-0.8
P/S (TTM)
9.88
P/FCF (TTM) · Derived
-0.48
Rev YoY
+215.2%
EPS YoY
+78.4%
Gross Margin
+83.2%
Op Margin
-291.1%
Net Debt
-$26.64M
Current Ratio
5.65
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology